Comparable stake leader
Lynx1 Capital Management LP
SEC ownership of Cullinan Therapeutics, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001789972.
Disclosed value leader
MPM BioImpact LLC
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- CGEM on Nasdaq
- Parsed ownership sources
-
13F, 13D/G, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Lynx1 Capital Management LP
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Lynx1 Capital Management LP
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001789972
- Issuer location
- Cambridge, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Cullinan Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Lynx1 Capital Management LP
Disclosed value leader
MPM BioImpact LLC
Comparable rows
50/50
Latest evidence
30 Jun 2026
13F
13D/G
3/4/5
Lead comparable stake: 14%
13D/G row: Lynx1 Capital Management LP
Showing 1-8 of 50 holder rows.
Quick read
Lynx1 Capital Management LP leads the comparable SEC ownership view at 14%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Lynx1 Capital Management LP's linked filing trail.
Comparable ownership
Top 5
Lynx1 Capital Management LP
14%
BIOTECHNOLOGY VALUE FUND L P
10%
PRICE T ROWE ASSOCIATES INC /MD/
6.2%
STATE STREET CORP
6%
Kynam Capital Management, LP
5.3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Lynx1 Capital Management LP |
13F
13D/G
3/4/5
Company · 10%+ Owner
|
14%
from 13D/G
|
$163,225,335
8,963,500 shares
|
— | 30 Jun 2026 |
| BIOTECHNOLOGY VALUE FUND L P |
13D/G
BVF PARTNERS L P/IL
|
10%
|
$119,631,397
6,491,123 shares
|
+$6,075,523 | 30 Jun 2026 |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13D/G
13F
T. Rowe Price Associates, Inc. · Company
|
6.2%
|
$70,512,258
3,825,950 shares
|
$0 | 30 Jun 2026 |
| STATE STREET CORP |
13D/G
13F
STATE STREET CORPORATION · Company
|
6%
|
$67,612,796
3,668,627 shares
|
$0 | 30 Jun 2026 |
| Kynam Capital Management, LP |
13F
13D/G
Company
|
5.3%
from 13D/G
|
$56,708,344
3,114,132 shares
|
— | 30 Jun 2026 |
| James E. Flynn |
13D/G
Deerfield Mgmt, L.P.
|
5%
|
$17,357,187
2,927,013 shares
|
$0 | 30 Sep 2025 |
| FRANKLIN RESOURCES INC |
13D/G
13F
Company
|
3.8%
|
$17,836,873
2,191,262 shares
|
$0 | 30 Sep 2024 |
| CITADEL ADVISORS LLC |
13D/G
13F
Kenneth Griffin · Company
|
3.4%
|
$11,794,219
1,988,907 shares
|
-$6,049,899 | 30 Sep 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$10,813,143.
Buys
$13,322,539
Insiders: 1
Sells
$2,509,396
Insiders: 5
Net
+$10,813,143
Shares: +1,708,145
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 1,874,057
Shares: 165,912
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 46,000 | $0 | $922,920 | -$922,920 |
| 3-6 | 0 | 8,000 | $0 | $116,996 | -$116,996 |
| 6-9 | 0 | 105,764 | $0 | $1,393,687 | -$1,393,687 |
| 9-12 | 1,874,057 | 6,148 | $13,322,539 | $75,792 | +$13,246,747 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 27 reporting-owner rows connected to Cullinan Therapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
27
Largest Forms 3/4/5 holder
Ansbert Gadicke
Net 12M change
+$10,813,143
Latest report
08 Sep 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Ansbert Gadicke | Director | $102,717,212 | Mixed | 22 Jun 2022 | ||
| UBS Oncology Impact Fund L.P. | 10%+ Owner | $95,297,419 | Mixed | 16 Sep 2021 | ||
| Lynx1 Capital Management LP | 10%+ Owner | $75,297,881 | +$13,322,539 | +21% | Filing P/S | 28 Oct 2025 |
| Morana Jovan-Embiricos | 10%+ Owner | $56,397,201 | Mixed | 24 Jun 2022 | ||
| Vision Scs F2 | 10%+ Owner | $55,775,322 | Mixed | 02 Aug 2022 | ||
| F2 Bioscience I 2017 Ltd | 10%+ Owner | $55,209,813 | Mixed | 21 Jun 2022 | ||
| Nadim Ahmed | President and CEO, Director | $5,654,919 | -$517,990 | -8.4% | Filing P/S | 24 Feb 2026 |
| Patrick Baeuerle | Chief Scientific Officer | $5,201,228 | Mixed | 17 Feb 2023 | ||
| Jennifer Michaelson | Chief Scientific Officer | $3,426,265 | -$1,615,833 | -32% | Filing P/S | 08 Sep 2026 |
| Corrine Savill | Chief Business Officer | $3,014,785 | Mixed | 18 Feb 2026 | ||
| Thomas Ebeling | Director | $2,426,489 | Mixed | 10 Jun 2024 | ||
| Jeffrey Alan Jones | Chief Medical Officer | $2,314,736 | -$178,948 | -7.2% | Filing P/S | 24 Feb 2026 |
| Jeffrey Trigilio | Chief Financial Officer | $2,166,809 | Mixed | 22 Feb 2024 | ||
| Jacquelyn L. Sumer | Chief Legal Officer | $1,855,243 | -$136,724 | -6.9% | Mixed | 30 Jun 2026 |
| Mary Kay Fenton | Chief Financial Officer | $1,817,757 | -$59,901 | -3.2% | Mixed | 30 Jun 2026 |
| Leigh Zawel | Chief Scientific Officer, Small Molecules | $869,521 | Mixed | 11 Feb 2022 | ||
| BVF PARTNERS L P/IL | 10%+ Owner | $799,446 | Mixed | 19 Jan 2023 | ||
| Keane Raymond T. | Chief Legal Officer | $300,585 | Mixed | 11 Feb 2022 | ||
| Nate Nguyen | Interim PAO and PFO | $216,408 | Mixed | 29 Mar 2024 | ||
| Mary Thistle | Director | Mixed | 16 Jun 2026 |
Recent insider transactions for Cullinan Therapeutics, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Jennifer Michaelson | CGEM | Common Stock | Sale | -4.79% | $172,560 | $21.57 | -8,000 | 158,844 | 08 Sep 2026 | Direct |
| Jennifer Michaelson | CGEM | Common Stock | Options Exercise | 2.46% | 4,000 | 166,844 | 08 Sep 2026 | Direct | ||
| Jennifer Michaelson | CGEM | Stock Option (Right to Buy) | Options Exercise | -4.82% | -4,000 | 78,987 | 08 Sep 2026 | Direct | ||
| Jennifer Michaelson | CGEM | Common Stock | Sale | -15.6% | $607,800 | $20.26 | -30,000 | 162,844 | 13 Aug 2026 | Direct |
| Jennifer Michaelson | CGEM | Common Stock | Options Exercise | 18.4% | 30,000 | 192,844 | 13 Aug 2026 | Direct | ||
| Jennifer Michaelson | CGEM | Stock Option (Right to Buy) | Options Exercise | -26.6% | -30,000 | 82,987 | 13 Aug 2026 | Direct | ||
| Jennifer Michaelson | CGEM | Common Stock | Sale | -4.68% | $142,560 | $17.82 | -8,000 | 162,844 | 06 Jul 2026 | Direct |
| Jennifer Michaelson | CGEM | Common Stock | Options Exercise | 2.4% | 4,000 | 170,844 | 06 Jul 2026 | Direct | ||
| Jennifer Michaelson | CGEM | Stock Option (Right to Buy) | Options Exercise | -3.42% | -4,000 | 112,987 | 06 Jul 2026 | Direct | ||
| Jacquelyn L. Sumer | CGEM | Common Stock | Award | 1.93% | 2,470 | 130,559 | 30 Jun 2026 | Direct | ||
| Mary Kay Fenton | CGEM | Common Stock | Award | 1.22% | 1,541 | 127,921 | 30 Jun 2026 | Direct | ||
| Anthony Rosenberg | CGEM | Stock Option (Right to Buy) | Award | 25,319 | 25,319 | 16 Jun 2026 | Direct | |||
| David D. Meek | CGEM | Stock Option (Right to Buy) | Award | 25,319 | 25,319 | 16 Jun 2026 | Direct | |||
| Stephen W. Webster | CGEM | Stock Option (Right to Buy) | Award | 25,319 | 25,319 | 16 Jun 2026 | Direct | |||
| Andrew R. Allen | CGEM | Stock Option (Right to Buy) | Award | 21,781 | 21,781 | 16 Jun 2026 | Direct | |||
| Mary Thistle | CGEM | Stock Option (Right to Buy) | Award | 25,319 | 25,319 | 16 Jun 2026 | Direct | |||
| Mittie Doyle | CGEM | Stock Option (Right to Buy) | Award | 21,781 | 21,781 | 16 Jun 2026 | Direct | |||
| Jennifer Michaelson | CGEM | Common Stock | Sale | -4.58% | $116,996 | $14.62 | -8,000 | 166,844 | 05 May 2026 | Direct |
| Jennifer Michaelson | CGEM | Common Stock | Options Exercise | 2.34% | 4,000 | 174,844 | 05 May 2026 | Direct | ||
| Jennifer Michaelson | CGEM | Stock Option (Right to Buy) | Options Exercise | -3.31% | -4,000 | 116,987 | 05 May 2026 | Direct | ||
| Jennifer Michaelson | CGEM | Common Stock | Sale | -4.47% | $125,440 | $15.68 | -8,000 | 170,844 | 05 Mar 2026 | Direct |
| Jennifer Michaelson | CGEM | Common Stock | Options Exercise | 2.29% | 4,000 | 178,844 | 05 Mar 2026 | Direct | ||
| Jennifer Michaelson | CGEM | Stock Option (Right to Buy) | Options Exercise | -3.2% | -4,000 | 120,987 | 05 Mar 2026 | Direct | ||
| Jennifer Michaelson | CGEM | Common Stock | Sale | -1.01% | $25,169 | $14.14 | -1,780 | 174,844 | 25 Feb 2026 | Direct |
| Jennifer Michaelson | CGEM | Common Stock | Sale | -2% | $52,106 | $14.47 | -3,601 | 176,624 | 24 Feb 2026 | Direct |
| Nadim Ahmed | CGEM | Common Stock | Sale | -3.34% | $195,562 | $14.47 | -13,515 | 390,803 | 24 Feb 2026 | Direct |
| Jeffrey Alan Jones | CGEM | Common Stock | Sale | -2.78% | $66,302 | $14.47 | -4,582 | 159,968 | 24 Feb 2026 | Direct |
| Jacquelyn L. Sumer | CGEM | Common Stock | Sale | -2.73% | $52,106 | $14.47 | -3,601 | 128,089 | 24 Feb 2026 | Direct |
| Jennifer Michaelson | CGEM | Common Stock | Sale | -0.96% | $24,510 | $13.99 | -1,752 | 180,225 | 23 Feb 2026 | Direct |
| Jeffrey Alan Jones | CGEM | Common Stock | Sale | -2.94% | $67,855 | $13.62 | -4,982 | 164,550 | 20 Feb 2026 | Direct |
| Jennifer Michaelson | CGEM | Common Stock | Options Exercise | 4.4% | 8,000 | 189,977 | 20 Feb 2026 | Direct | ||
| Jennifer Michaelson | CGEM | Common Stock | Sale | -6.06% | $165,366 | $14.08 | -11,742 | 181,977 | 20 Feb 2026 | Direct |
| Jennifer Michaelson | CGEM | Stock Option (Right to Buy) | Options Exercise | -6.02% | -8,000 | 124,987 | 20 Feb 2026 | Direct | ||
| Jacquelyn L. Sumer | CGEM | Common Stock | Sale | -2.76% | $50,966 | $13.62 | -3,742 | 131,690 | 20 Feb 2026 | Direct |
| Nadim Ahmed | CGEM | Common Stock | Sale | -3.89% | $223,109 | $13.62 | -16,381 | 404,318 | 20 Feb 2026 | Direct |
| Mary Kay Fenton | CGEM | Common Stock | Sale | -3.36% | $59,901 | $13.62 | -4,398 | 126,380 | 20 Feb 2026 | Direct |
| Jacquelyn L. Sumer | CGEM | Stock Option (Right to Buy) | Award | 230,000 | 230,000 | 18 Feb 2026 | Direct | |||
| Jeffrey Alan Jones | CGEM | Stock Option (Right to Buy) | Award | 300,000 | 300,000 | 18 Feb 2026 | Direct | |||
| Nadim Ahmed | CGEM | Stock Option (Right to Buy) | Award | 828,000 | 828,000 | 18 Feb 2026 | Direct | |||
| Corrine Savill | CGEM | Stock Option (Right to Buy) | Award | 175,000 | 175,000 | 18 Feb 2026 | Direct | |||
| Mary Kay Fenton | CGEM | Common Stock | Award | 110.8% | 68,750 | 130,778 | 18 Feb 2026 | Direct | ||
| Mary Kay Fenton | CGEM | Stock Option (Right to Buy) | Award | 137,500 | 137,500 | 18 Feb 2026 | Direct | |||
| Jennifer Michaelson | CGEM | Common Stock | Award | 44.8% | 57,500 | 185,719 | 18 Feb 2026 | Direct | ||
| Jennifer Michaelson | CGEM | Stock Option (Right to Buy) | Award | 115,000 | 115,000 | 18 Feb 2026 | Direct | |||
| Jennifer Michaelson | CGEM | Common Stock | Sale | -0.32% | $5,004 | $12.03 | -416 | 128,219 | 12 Feb 2026 | Direct |
| Jennifer Michaelson | CGEM | Common Stock | Sale | -3.02% | $49,200 | $12.30 | -4,000 | 128,635 | 22 Jan 2026 | Direct |
| Mary Kay Fenton | CGEM | Common Stock | Award | 0.04% | 27 | 62,028 | 31 Dec 2025 | Direct | ||
| Nadim Ahmed | CGEM | Common Stock | Sale | -2.3% | $99,319 | $10.01 | -9,922 | 420,699 | 23 Dec 2025 | Direct |
| Jennifer Michaelson | CGEM | Common Stock | Sale | -1% | $13,463 | $10.01 | -1,345 | 132,635 | 19 Dec 2025 | Direct |
| Jacquelyn L. Sumer | CGEM | Common Stock | Sale | -2.51% | $33,652 | $9.67 | -3,480 | 135,432 | 18 Dec 2025 | Direct |
* marks a reported price that did not pass the local price check.